The US Food and Drug Administration (FDA) has granted approval to Novo Nordisk's Wegovy for its effectiveness in reducing heart risks. Wegovy, a medication designed to aid in weight management, has shown promising results in clinical trials.
Individuals who are overweight or obese often face an increased risk of developing heart disease. By addressing weight management, Wegovy aims to help lower this risk and improve overall cardiovascular health.